| Category |
Transplantation |
| Manuscript Type |
Expert Consensus |
| Article Title |
Induction therapy in kidney transplant recipients: A consensus statement of Indian Society of Organ Transplantation
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Vivek B Kute, Manish Ramesh Balwani, Jigar B Shrimali, Amit Pasari, Vijay Kher, Mohan Punabhai Patel, Deodatta Chafekar, Swarnalata Guditi, Pratik Das, Gireesh Mathihally Siddaiah, Suraj Mohan Godara, Vinantt Bhargava, Anurag Gupta, Vishal Ramteke, Nishant Deshpande, Priyanka Tolani, Narayan Prasad, Radhika Krishna Patil, Ravi Mohanka, Sandeep Mahajan, Sourabh Sharma, Subho Banerjee, Divyesh P Engineer, Dhananjai Agarwal, Pranjal Kashiv, Arpita Lahiri, Narayan Prasad, Dinesh Khullar and Aneesh Srivastava |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Manish Ramesh Balwani, DM, MD, Professor, Department of Nephrology, Saraswati Kidney Care Center, 13, Jaitala Road, Near Jaiprakash Nagar Metro Station, New Sneh Nagar, Nagpur 440015, Maharashtra, India. balwani.manish@yahoo.com |
| Key Words |
Kidney transplant; Induction therapy; Rabbit antithymocyte globulin; IL-2 receptor blockers; Rituximab; Consensus; Indian Society of Organ Transplantation |
| Core Tip |
Kidney transplantation is the most common solid organ transplantation in India, yet induction immunosuppression practices vary widely across centers. The Indian Society of Organ Transplantation (ISOT) conducted a nationwide survey and identified significant heterogeneity in induction therapy choice, dose, and duration. Through a structured Delphi consensus, ISOT developed 16 statements to guide practice. Rabbit antithymocyte globulin (rATG) remains the preferred induction for high immunological risk and deceased donor recipients, while interleukin-2 receptor anatagonists or low-dose rATG is suitable for low-risk cases. Rituximab is recommended for ABO-incompatible transplants. These India-specific guidelines provide a standardized framework to optimize patient outcomes and rationalize induction therapy. |
| Citation |
Kute VB, Balwani MR, Shrimali JB, Pasari A, Kher V, Patel MP, Chafekar D, Guditi S, Das P, Gireesh MS, Godara SM, Bhargava V, Gupta A, Ramteke V, Deshpande N, Tolani P, Prasad N, Patil RK, Mohanka R, Mahajan S, Sharma S, Banerjee S, Engineer DP, Agarwal D, Kashiv P, Lahiri A, Prasad N, Khullar D, Srivastava A. Induction therapy in kidney transplant recipients: A consensus statement of Indian Society of Organ Transplantation. World J Transplant 2025; In press |
| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
